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e.2012.07Abstract Background: Weight loss (5–10%) improves obesity-associated cardiovascular risk
factors. The aim of this work was to study the effect of 2 commonly performed bariatric surgical
procedures; laparoscopic Roux-en-Y gastric bypass (RYGBP) and laparoscopic gastric band
(BAND), on the cardiovascular risk proﬁle in morbidly obese patients and its correlation with
the plasma apolipoprotein (apo) A-IV level.
Patient and method: This study was carried prospectively on 34 patients scheduled for bariatric sur-
gery. They were randomly assigned into two groups; group 1 = BAND (18 cases), group 2 = gas-
tric bypass RYGBP (16 cases). Both groups were studied preoperatively and twelve months after
surgery. Data collected included changes of body mass index (BMI), blood pressure, fasting blood
sugar, fasting serum insulin, insulin resistance (HOMA-IR) and lipid proﬁle. In addition, apo A-IV
was determined by the Western blot technique.
Results: The results demonstrated a highly signiﬁcant reduction in body weight as determined by
reduction in the BMI in both groups I & II compared to preoperative measurements. Moreover,
both groups had a signiﬁcantly lower systolic blood pressure, fasting blood glucose (FBG), fasting
serum insulin and HOMA-IR twelve months after operation. The changes in BMI, systolic blood
pressure; FBG and HOMA-IR were signiﬁcantly more in group II than in group I. The lipid proﬁles
in group I & II before surgery were similar. The HDL-cholesterol was signiﬁcantly higher in bothoo.com (H.M. Demerdash),
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Figure 1 Shows changes in apo A-IV
by the western blotting technique an
The Apo A-IV was signiﬁcantly incr
groups, however, the increase (estima
signiﬁcantly greater in group II (Tabl
18 H.M. Demerdash et al.groups I & II 12 months after surgery. In addition, apo A-IV levels increased after surgery in both
groups.
Conclusion: Both gastric band and gastric bypass are associated with signiﬁcant improvement of
the cardiovascular risk proﬁle, although it is more pronounced after gastric bypass. The improve-
ment correlates well with the increase of apo A-IV in both groups.
Thus Apo A-IV may play a positive role in improving the cardiovascular risk proﬁle after bariatric
surgery.
ª 2012 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
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afterbefore
.8
.7
.6
.5
.4
.3
.2
1818
*
Se
ru
m
 A
po
A-
IV
1.2
1.0
.8
.6
.4
*
Se
ru
m
 A
po
A-
IV
(a)
(b)1. Introduction
Overweight and obesity are rapidly growing to an epidemic
proportion all over the world. Severe obesity (BMI P40 Kg/
m2) is associated with signiﬁcant medical co-morbidities as well
as reduced life expectancy. Health service use and medical
costs associated with obesity related diseases have increased
dramatically in the last years.1 Obesity may affect the heart
through its inﬂuence on known risk factors such as dyslipide-
mia, hypertension, impaired glucose tolerance, inﬂammatory
markers, obstructive sleep apnea/hypoventilation, and the
prothrombotic state. It is well known that weight reduction
improves obesity-related cardiovascular risk factors.2 The use
of conventional weight-loss diets and drug therapy has been
shown to decrease the risk for conversion from impaired
glucose tolerance to overt diabetes and can maintain blood
pressure reductions over prolonged periods of follow-up.
However, they may be associated with toxic effect, also they
are usually ineffective for severe obesity, and bariatric surgery
has been proposed as an alternative therapy.3 More dramatic
weight loss after bariatric surgery has been associated with
even greater health beneﬁts, especially patients with diabetes4
(Figs. 1 and 2).
Apolipoproteins, are the protein components of lipoprotein
particles, they play an active role in the lipid metabolism. In
addition to the well-known apolipoproteins, apo A-IV apoli-
poprotein is a 46-KD glycoprotein. It is synthesized by the
small intestine in response to lipid absorption and the forma-
tion of chylomicrons.5 The majority of apo A-IV in the circu-
lation exists as free protein while the remainder is associated
with circulating HDL. It is also produced in the hypothalamic
arcuate nucleus. Despite its responsiveness to lipid intake, the
exact function for apo A-IV has not yet been widely recog-
nized. It has been proposed to play many functions in vivo
including: food intake regulation, demonstrating it to be a sati-
ety factor6,7 gastrointestinal motility, structural constituent of
lipoproteins, protection against lipid oxidation and atheroscle-
rosis, recently identiﬁed as an anti-inﬂammatory protein and
can also mimic many of the roles of apo A-I in terms of lipid
binding and cholesterol efﬂux.8after surgery as determined
d detected by densitometry.
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The aim of this work was to study the effect of 2 commonly per-
formed bariatric surgical procedures; laparoscopic Roux-en-Y
gastric bypass (RYGBP) and laparoscopic gastric bandPatients before and after RYGBP surgery  
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Figure 2 (a) Serum apo A-IV densitometric changes (vertical
axis) before and after BAND procedure. (b) Serum apo A-IV
densitometric changes (vertical axis) before and after RYGBP
procedure.
Table 1 Demographic data of the study population.
Differential effects of gastric bypass and banding on the cardiovascular risk proﬁle 19(BAND), on the cardiovascular risk proﬁle in morbidly obese
patients and its correlation with apo A-IV level.Group I
(BAND)
n= 18
Group II
(RYGBP)
n= 16
P-value
Age (years) 37 ± 6 39 ± 4.5 0.38
Sex (M/F) 3/15 2/16 0.67
BMI (kg/m2) 45.8 ± 2.7 46.2 ± 2.56 0.336
Body weight (kg) 138.7 ± 22.98 142.7 ± 22.6 0.2213. Patients and methods
This prospective study was conducted in the Department of
Surgery at Alexandria Main University Hospital during the
period from 2008 through 2010. The study was approved by
the Ethics Committee of the Faculty of Medicine of the
University of Alexandria (Alexandria, Egypt). An informed
consent was obtained from all patients included in the study.
Forty patients were considered for surgery based upon satis-
faction of the minimal criteria for bariatric surgical treatment,
as determined by the Consensus Development Panel of the
National Institutes of Health.9 In brief, surgery may be consid-
ered in those persons with body mass index (BMI) greater
than 40 kg/m2, or greater than 35 kg/m2, when there are co-
morbidities which are life-threatening or detrimental to activi-
ties of daily living. Patients were randomly assigned by using
sealed-envelope technique to either laparoscopic gastric band
(BAND) as group I or laparoscopic Roux-en-Y gastric bypass
(RYGBP) as group II.
3.1. Surgical procedures
The surgical procedure for the BAND consisted of placement
of the Swedish adjustable gastric band (Obtech and Ethicon
Endo-Surgery) around the proximal stomach. We used the
pars ﬂaccida technique. A retrogastric tunnel was created
above the peritoneal reﬂection of the bursa omentalis. The
band was then passed through this tunnel and locked. The
anterior wall of the stomach below the band is then secured
to the wall above the band with interrupted non absorbable
gastro-gastric sutures to avoid slippage. The band placed
around the upper stomach creates a small pouch with a nar-
rowed outlet. The inner surface of the band is inﬂatable and
connected by kink-resistant tubing to the access port. The port
was placed subcutaneously permitting postoperative percuta-
neous stoma size adjustment. The ﬁrst ﬁlling of the gastric
band was performed 4 to 6 weeks postoperatively.
The surgical procedure for RYGBP consisted of creation of
a 15- to 30-mL pouch that was isolated from the distal stom-
ach by several applications of a linear stapler. The jejunum
is divided 50 cm distal to the ligament of Treitz, and the distal
limb is connected to the gastric pouch (antecolic-antegastric),
using a linear cutter, creating an alimentary Roux limb. The
proximal bowel segment (biliopancreatic limb) is connected
to the alimentary limb through a jejunojejunostomy 100 to
150 cm distal to the gastrojejunostomy. For patients whose
BMI was less than 50, a 100-cm Roux limb was measured;
for those whose BMI was greater than 50, we used a 150-cm
limb.11
Before surgery and 12 months after, blood samples were
taken after overnight fast of at least 12 h, and patients were
weighed in a light gown. Blood samples were used for determi-
nation of lipid proﬁle, glucose and insulin as well as Western
blot (WB) assay to detect apo A-IV. In all pre-menopausal
women, lipids were studied within the ﬁrst 5 days of the men-
strual cycle to avoid hormonal interference that may modify
lipid pattern. Other collected data included systolic and dia-
stolic blood pressure.Fasting plasma glucose (FBG) was measured by the hexo-
kinase method and plasma insulin was determined using an
IMMULITE 2500 autoanalyzer (Siemens Medical Diagnos-
tics) in an immunometric chemiluminescent test with two bind-
ing sites (noncompetitive) on solid phase. The homeostasis
model of assessment of insulin resistance (HOMA-IR) was
then calculated by the following formula: fasting serum insulin
concentration (mIU/mL) · blood glucose concentration
(mmol/L)/22.5.12
Total cholesterol, HDL-cholesterol and triglycerides were
measured enzymatically using commercial kits. The apolipo-
protein B100 was measured using enzyme linked immunoas-
says. LDL cholesterol was calculated using Friedwald’s
formula, since no subject had triglycerides h350 mg/dl.9
Blood samples for apo A-IV estimation were collected in
EDTA vacutainers, centrifuged at low speed (3000 rpm) and
serum was frozen at 80 C until assayed. Apo A-IV level
was estimated using the western blot technique.
3.2. Apo A-IV assay using the western blot technique
A single gel was run for each patient and loaded with 2 sam-
ples; one before and the second after surgery. Western blot
(WB) assays to detect apo A-IV were run using 10% sodium
dodecyl sulfate gel electrophoresis and transferred to Immobi-
lon membranes of Millipore. IgG anti-human apo A-IV was
used as the primary antibody at 1/500 dilution (with blocking
solution). Horseradish peroxidase (HRP)-conjugated pig anti-
rabbit IgG at 1/15,000 dilution (with blocking solution) was
used as the secondary antibody (Dako, Glostrup, Denmark).
Non-speciﬁc binding was prevented using a blocking solution
(phosphate-buffered saline (PBS) with bovine serum albumin
(BSA)) at 2% (w/v, BSA/PBS). WBs were developed using
the Super-Signal West Pico Chemiluminescent substrate for
HRP detection (Pierce, Rockford, IL, USA). Relative quan-
tities and optical density were estimated by densitometric
scanning (Phoretix 1D gel Analysis Software Non-linear
Dynamics, Newcastle, UK).13
3.3. Statistical analysis
Data were prospectively collected. All data analyses were
performed with the Statistical Package for the Social Sciences
version 15 software (SPSS, Inc., Chicago, IL). Results are
expressed as mean ± standard deviation. The Student’s t test
and paired t test were used for continuous variables. The
chi-squared test was used for category variables. Spearman
correlation coefﬁcient was used to detect the correlation
between different variables. All P-values were two sided. A
value of P 6 0.05 was considered statistically signiﬁcant.
Table 2 Body mass index (BMI), fasting plasma glucose (FPG), fasting insulin and HOMA-IR before and 12 months after surgery.
Group I (BAND) n= 18 Group II (RYGBP) n= 16 P2
Preoperative 12 Months after
operation
P Preoperative 12 Months after
operation
P
BMI 45.8 ± 2.7 37.1 ± 1.6 0.006* 46.2 ± 2.56 32.0 ± 2.8 0.0013* 0.0013*
%Body weight decrease 26.25 ± 22.13 31.5 ± 19.58 0.025
FBG (mg/dl) 108.0 ± 18.4 92.5 ± 12.0 0.033* 111.0 ± 17.46 80.0 ± 8.9 0.012* 0.0358*
Serum insulin (mIU/mL) 22.4 ± 3.65 9.85 ± 0.65 0.001* 23.5 ± 4.01 8.12 ± 0.76 0.0001* 0.042*
HOMA-IR 2.62 ± 0.625 1.75 ± 0.55 0.0158* 2.71 ± 0.71 1.23 ± 0.68 0.011* 0.046*
* Statistically signiﬁcant result.
P: comparison with the preoperative level within the same group.
P2: Comparison between the changes in the two groups.
Table 3 Systolic and diastolic blood pressure (BP) in groups I & II; before and 12 months after surgery.
Group I (BAND) n= 18 Group II (RYGBP) n= 16 P2
Preoperative 12 Months P Preoperative 12 Months P
Systolic BP (mmHg) 146.2 ± 17.82 131.9 ± 10.3 0.001 148.6 ± 18.0 126.7 ± 9.9 0.001 0.003*
Diastolic BP (mmHg) 92.5 ± 10.0 84.5 ± 6.4 0.231 91.5 ± 10.2 81.5 ± 8.8 0.01 0.013*
* Statistically signiﬁcant result.
P: Comparison with the preoperative level within the same group (paired t test).
P2: Comparison between the changes in the two groups (student’s t test).
Table 4 Plasma lipid proﬁle in groups I & II before and 12 months after surgery.
Group I (BAND) n= 18 Group II (RYGBP) n= 16 P2
Preoperative 12 Months P Preoperative 12 Months P
Total cholesterol (mg/dl) 247.1 ± 33.8 196.2 ± 23.5 0.001 246.71 ± 33.8 178.8 ± 19.3 0.001 0.001*
HDL Cholesterol (mg/dl) 41.4 ± 7.6 44.5 ± 4.3 0.106 40.8 ± 6.5 47.4 ± 3.5 0.035* 0.106
LDL Cholesterol (mg/dl) 162.4 ± 62.2 110.3 ± 16.8 0.001 160.4 ± 61.28 67.4 ± 23.5 0.001 0.0001*
Triglycerides (mg/dl) 172.0 ± 97.7 143.5 ± 40.1 0.001 169.0 ± 98.1 101.5 ± 23.3 0.001 0.0001*
Apo-B 100 (mg/dl) 112.3 ± 6.9 78.3 ± 6.1 0.001* 109.3 ± 7.7 72.5 ± 7.6 0.001* 0.032*
Apo-B100/LDL-C 0.69 ± 0.233 0.70 ± 0.285 0.26 0.68 ± 0.33 1.09 ± 0.277 0.106 0.098
ApoA-IV(optical density) 0.23 ± 0.08 0.86 ± 0.1 0.001* 0.31 ± 0.09 1.11 ± 0.1 0.001* 0.034*
* Statistically signiﬁcant result.
P: Comparison with the preoperative level within the same group (paired t test).
P2: Comparison between the changes in the two groups (student’s t test).
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Out of 40 patients originally randomized to either BAND or
RGBP, 34 patients completed the 12 month follow up and con-
stituted the material of this study. They were 18 patients in the
BAND group and 16 patients in the RGBP group. The preop-
erative clinical characteristics of each of the two studied groups
are shown in Table 1. There were no signiﬁcant differences in
age, sex, body weight, or BMI between the two surgical groups.
Twelve months after surgery (Table 2), the body mass index
(BMI) decreased from 45.8 ± 2.7 and 46.2 ± 2.56 to
37.1 ± 1.6 and 32.0 ± 2.7 in group I (BAND) and group II
(RGBP) respectively. This was associated with signiﬁcant
improvement of glucose metabolism parameters in both
groups. HOMA-IR decreased from 2.62 ± 0.625 and
2.71 ± 0.71to 1.75 ± 0.55 and 1.23 ± 0.68 in group I and
group II, respectively. The changes in BMI, body weight,FBG, fasting insulin, and HOMA-IR were signiﬁcantly greater
in RGBP group compared to those in BAND group (Table 2).
Other cardiovascular risk factors that were determined are
shown in Tables 3 and 4. There was a signiﬁcant reduction of
total cholesterol, LDL cholesterol, triglycerides and Apo B 100
after surgery in both groups. On the other hand, the HDL cho-
lesterol increased from 41.4 ± 7.6 mg/dl, 40.8 ± 3.5 preopera-
tively to 44.5 ± 4.3 and 47.4 ± 3.5 after surgery in groups I &
II, respectively. All lipid proﬁle parameters showed a greater
change after surgery in group II than in group I (Table 4). Sim-
ilarly, Apo B 100 level was reduced from 112.3 ± 6.9 mg/dl to
78.3 ± 6.1 mg/dl in group I and from 109.3 ± 7.7 mg/dl to
72.5 ± 7.6 mg/dl in group II after surgery. The decrease in
Apo B100 was signiﬁcantly greater in group II.
There was a statistically signiﬁcant correlation between the
change of the arbitrary value of apo A-IV and those of all mea-
sured cardiovascular risk factors after surgery (Table 5).
Table 5 Correlation between apo A-IV change and cardio-
vascular risk factors changes after surgery (n= 34).
R P
Apo A-IV # BMI 0.462 0.0015*
Apo A-IV # systolic B.P. 0.398 0.014*
Apo A-IV # Total cholesterol 0.46 0.0023*
Apo A-IV # HOMA-IR 0.365 0.046*
Apo A-IV # HDL 0.45 0.036*
Apo A-IV # triglycerides 0.39 0.041*
* Statistically signiﬁcant result.
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The ﬁeld of bariatric surgery has evolved over the past
50 years; weight loss has almost been over shadowed by the
extraordinary effects on obesity related co-morbidities such
as hyperlipidemia, hypertension, and diabetes. This type of
surgery was known to induce marked weight reduction, and
it had a remarkable effect on circulating lipid levels in severely
hyperlipidemic patients.14 In this study we examined the effects
of weight loss after bariatric surgery on reductions in cardio-
vascular risk factors.
In the present study, the cardiovascular risk factors includ-
ing systolic blood pressure, insulin resistance, lipid proﬁle and
BMI were studied before and one year after surgery. Results
revealed a signiﬁcant improvement of the lipids proﬁle, includ-
ing apo B100 in both groups; group I (BAND) and group II
(RYGBP). Improvement involved a signiﬁcant decrease in to-
tal cholesterol, LDL cholesterol and triglycerides. However,
the decrease was greater in group II than in group I. The great-
er reduction in group II than I could be explained by the great-
er degree of weight loss and lower energy intake following
RYGBP. While gastric band (BAND) is a purely restrictive
procedure, the mechanism for weight loss after Roux-en-Y
gastric bypass include: (i) restriction of food intake by small
gastric pouch and narrow gastrojejunostomy; (ii) mild degree
of malabsorption caused by intestinal bypass; and (iii) abdom-
inal discomfort caused by ingestion of concentrated sweets. In
addition, the surgical disruptions of the various autonomic
nerve ﬁbers that innervate the foregut, may also affect both
short- and long-term regulation of gastrointestinal hormonal
secretion.15
Our study was in agreement with other studies, which
reported that subjects with hypercholesterolemia at baseline
had normal blood cholesterol levels one year after bariatric
surgery. This means that there is no need for lipid-lowering
medications any more.11,15,16 There was an additional beneﬁ-
cial effect, in which HDL-cholesterol levels signiﬁcantly
increased in both groups I & II. This was in agreement with
other studies which stated that dyslipidemia associated with
obesity is characterized by increased fasting triglyceride and
decreased HDL-cholesterol concentrations.10,11,15,17 This im-
proved lipid proﬁle was associated with increased apo A-IV
in both groups, with more signiﬁcant increase in group II.
The increased apo A-IV observed in our study may be due
to recovery of intestinal function, which supports the concept,
that plasma apo A-IV is synthesized exclusively by the intes-
tines as mentioned before. Moreover, in a previous study by
Tso et al.7, they stated that chronic consumption of a high-
fat diet signiﬁcantly elevates plasma apo A-IV levels. Thiselevation is observed during the ﬁrst week of high fat con-
sumption but disappears during the second week; this proves
that auto-regulation of intestinal apo A-IV production in re-
sponse to diets high in fat. Thus obese persons become less
responsive to fat after chronic high-fat diet consumption.
Insulin resistance, in morbidly obese patients is associated
with alteration of lipid metabolism, which may be due to asso-
ciated decreased activity of lipoprotein lipase and increased
production of small dense LDL. Insulin resistance also results
in elevated free fatty acids secondary to hydrolysis of stored
triglycerides in adipose tissues.16–21 Weight loss improves insu-
lin sensitivity proved by HOMA-IR as we also observed in our
patients after surgery. Meneghini22 suggested that laparo-
scopic RYGBP has a beneﬁcial effect on glucose metabolism
and serum lipid composition in obese type 2 diabetes mellitus
(T2DM) patients. They reported that sustained weight loss was
associated with maintenance of euglycemia in postoperative
obese T2DM patients.
Reversibility of insulin resistance following bariatric
surgery is supported by the signiﬁcant decrease in plasma glu-
cose and improved insulin levels as represented by signiﬁcant
reduction in the HOMA-IR. Previous study reported that in
morbidly obese subjects the HOMA-IR reference values con-
sidered to represent insulin resistance were around 3.5–3.8.16
Therefore reduction in HOMA-IR values in this study was
to a value of one, suggests that insulin resistance was resolved
in both groups. It is well known that stored triglycerides are
hydrolyzed to fatty acids and glycerol by the hormone sensitive
lipase, whose action is inhibited by insulin.23 Increased lipoly-
sis, a characteristic of obesity, leads to an increase in circulat-
ing free fatty acids FFA, which are transported and oxidized in
skeletal muscle. The increased FFA oxidation subsequently
leads to inhibition of glucose oxidation. In fact, obese subjects
tend to oxidize more lipids than carbohydrates.24 Also, the de-
tected changes in apolipoproteins in both groups, especially
group II following RYGBP resulting in a less atherogenic phe-
notype may contribute to the improvement in cardiovascular
risks which is in agreement with other studies.21,25,26
Weight loss of approximately 0.5 kg per week can be
achieved by diet alone, and can lead to a decrease in triglycer-
ides, low-density lipoprotein, and total cholesterol. However
an overall improvement in the lipid panel; was obtained with
a high-dose 3-hydroxy-3-methylglutaryl coenzyme A reductase
(HMG Co A) inhibitor therapy. In a study performed in pa-
tients treated with Cholestagel, a new potent bile acid seque-
strant, LDL cholesterol decreased by 19.1%.27 In addition,
Adams et al.28 stated that weight loss associated with bariatric
surgery is more sustainable, and that the improvement in the
lipid proﬁle may be superior after surgery.
Fabris et al.24 have shown that the weight loss after gastric
banding produces a decrease in fasting triglyceride levels, an
elevation of high-density lipoprotein-cholesterol levels to nor-
mal, and improved total cholesterol to high density lipopro-
tein-cholesterol ratio. Although weight loss associated with
bariatric surgery improved dyslipidemia, the changes in the
lipid panel appear to be procedure-dependent.15,16 Menegh-
ini22 noted 90 percent improvement in cholesterol and triglyc-
eride levels after gastric bypass or biliopancreatic diversion (or
duodenal switch) as compared to 50- to 70-percent improve-
ment with gastric banding and gastroplasty. It appears that
the malabsorptive aspect of these mixed procedures, in addi-
tion to the associated weight loss, plays an important role in
22 H.M. Demerdash et al.improvement of the lipid proﬁle in morbidly obese patients in
contrast to weight loss secondary to diet restriction alone.21 In
a Chinese study, results revealed that combination of Chinese
medicinal herbs stimulates Apo A-IV promoter activity in gut
cells and is associated with reduction of Triglyceride contents
in adipocytes and therefore increased apoA-IV level, which
may be used to treat obesity.29
However, in contrast to our results; Lingenhel et al. studied
apo A-IV in obese young adolescents undergoing diet restric-
tion; they concluded that plasma apoA-IV level decreased
markedly in overweight adolescents undergoing short-term
weight reduction. The decrease is not directly related to the de-
gree of weight loss.27
The result of apo A-IV in this study showed a greater in-
crease in group II probably related to the greater degree of
weight loss observed after RYGBP as well as regulation of gas-
trointestinal hormonal secretion such as ghrelin. This result
agrees with the results of previous studies.20,22 Another study
reported apo A-IV to be frequently elevated in rodent models
of obesity and obese humans.8 Thus apo A-IV resistance may
represent a signiﬁcant factor known to occur with leptin in
obesity, which also regulates apo A-IV secretion.21,28 It has
been demonstrated that intravenous injection of apo A-IV into
rats causes a reduction in food intake.13,22 This observation
may be potentially explained by the complex, multi-factorial
regulation of food intake.29
Plasma lipoproteins, such as high-density lipoprotein
(HDL), can serve as carriers for a wide range of proteins that
are involved in lipid metabolism, inﬂammation and atheroscle-
rosis.9 The identiﬁcation of HDL-associated proteins is essen-
tial with regards to understanding these processes at the
molecular level. Therefore, in this study, we performed Wes-
tern blot analysis to identify apo A-IV associated with human
HDL. This technique proved to be a powerful and comprehen-
sive tool for the identiﬁcation of proteins on HDL.13
In this study we did not use ELISA technique, because ELI-
SA works on native protein, while Western works on dena-
tured proteins. Thus ELISA cannot give any information on
the purity of the protein. Moreover, cross reactivity of any
antibody can’t be visualized in ELISA but can be visualized
with WB. Therefore, ELISA can sometimes underestimate
proteins.30
In conclusion, both gastric band and gastric bypass are
associated with signiﬁcant improvement of the cardiovascular
risk proﬁle, although it is more pronounced after gastric by-
pass. The improvement correlates well with increase of apo
A-IV in both groups.
Thus, Apo A-IV may play a positive role in improving the
cardiovascular risk proﬁle after bariatric surgery and can be a
useful tool in clinical monitoring of the patients.References
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